These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 31094901

  • 1. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study.
    Vieta E, Florea I, Schmidt SN, Areberg J, Ettrup A.
    Int Clin Psychopharmacol; 2019 Jul; 34(4):153-160. PubMed ID: 31094901
    [Abstract] [Full Text] [Related]

  • 2. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study.
    Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I.
    Int Clin Psychopharmacol; 2020 Nov; 35(6):305-312. PubMed ID: 32784346
    [Abstract] [Full Text] [Related]

  • 3. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L.
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH.
    Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
    [Abstract] [Full Text] [Related]

  • 8. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
    Inoue T, Nishimura A, Sasai K, Kitagawa T.
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
    Findling RL, DelBello MP, Zuddas A, Emslie GJ, Ettrup A, Petersen ML, Schmidt SN, Rosen M.
    J Am Acad Child Adolesc Psychiatry; 2022 Sep; 61(9):1106-1118.e2. PubMed ID: 35033635
    [Abstract] [Full Text] [Related]

  • 16. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
    Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR.
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
    [Abstract] [Full Text] [Related]

  • 17. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G, Gislum M, Filippov G, Montgomery S.
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
    Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B.
    J Psychiatr Res; 2018 Jun; 101():72-79. PubMed ID: 29554497
    [Abstract] [Full Text] [Related]

  • 19. Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: The role of age at first onset and change in depressive symptoms.
    Xue L, Bocharova M, Young AH, Aarsland D.
    J Affect Disord; 2024 Sep 15; 361():74-81. PubMed ID: 38838790
    [Abstract] [Full Text] [Related]

  • 20. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.
    Mills NT, Sampson E, Fourrier C, Baune BT.
    Int J Neuropsychopharmacol; 2021 Apr 21; 24(4):314-321. PubMed ID: 33269395
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.